Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2380-2393
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2380
Predicting the prognosis of hepatic arterial infusion chemotherapy in hepatocellular carcinoma
Qi-Feng Wang, Zong-Wei Li, Hai-Feng Zhou, Kun-Zhong Zhu, Ya-Jing Wang, Ya-Qin Wang, Yue-Wei Zhang
Qi-Feng Wang, Ya-Jing Wang, Ya-Qin Wang, Yue-Wei Zhang, Department of Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, Beijing 102218, China
Qi-Feng Wang, Zong-Wei Li, Hai-Feng Zhou, Kun-Zhong Zhu, Department of Hepatobiliary and Pancreatic Surgery, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China
Co-corresponding authors: Ya-Qin Wang and Yue-Wei Zhang.
Author contributions: Wang QF drafted the manuscript and conception; Li ZW, Zhou HF, and Zhu KZ performed the literature search, and design; Wang YJ collected and assessed the data; Wang YQ and Zhang YW were contributed equally to this work responsible for the conception of the study, final editing, and review of the manuscript and as co-corresponding authors; all authors contributed to the article and approved the submitted version.
Supported by the Research Fund of Beijing Tsinghua Changgung Hospital, No. 12021C11016.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yue-Wei Zhang, Academic Research, Chief Doctor, Department of Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, No. 168 Litang Road, Beijing 102218, China. zhangyuewei1121@sina.com
Received: December 18, 2023
Revised: January 19, 2024
Accepted: April 3, 2024
Published online: June 15, 2024
Processing time: 179 Days and 23.1 Hours
Core Tip

Core Tip: Hepatic artery infusion chemotherapy (HAIC) has good clinical efficacy and high safety, and it has become one of the main treatment options for patients with intermediate to advanced hepatocellular carcinoma (HCC). Through predicting the prognosis of HAIC, appropriate patients can be screened for HAIC, and the overall efficacy of HAIC in HCC patients can improve. This review summarized the strategies currently used to predict the efficacy of HAIC in middle and advanced HCC, analyzed each marker's ability to predict HAIC efficacy, and provided a reference for the clinical selection of an appropriate HAIC prediction modality.